Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

Article  PubMed  Google Scholar 

Herzog BH, Devarakonda S, Govindan R. Overcoming chemotherapy resistance in SCLC. J Thorac Oncol. 2021;16(12):2002–15.

Article  CAS  PubMed  Google Scholar 

Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine. Molecules. 2019;25(1):112.

Article  PubMed  PubMed Central  Google Scholar 

Su X, Zhang X, Liu W, Yang X, An N, Yang F, Sun J, Xing Y, Shang H. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. Semin Cancer Biol. 2022;86(Pt 2):929–42.

Article  CAS  PubMed  Google Scholar 

Gerken LRH, Gerdes ME, Pruschy M, Herrmann IK. Prospects of nanoparticle-based radioenhancement for radiotherapy. Mater Horiz. 2023;10(10):4059–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu ZR, Qiao P. Drug delivery in cancer therapy, quo vadis? Mol Pharm. 2018;15(9):3603–16.

Article  CAS  PubMed  Google Scholar 

Castillo RR, Colilla M, Vallet-Regi M. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv. 2017;14(2):229–43.

Article  CAS  PubMed  Google Scholar 

Saadat M, Manshadi MKD, Mohammadi M, Zare MJ, Zarei M, Kamali R, Sanati-Nezhad A. Magnetic particle targeting for diagnosis and therapy of lung cancers. J Control Release. 2020;328:776–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. Int J Nanomedicine. 2017;12:8483–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coccia M, Wang L. Path-breaking directions of nanotechnology-based chemotherapy and molecular cancer therapy. Technol Forecast Soc Chang. 2015;94:155–69.

Article  Google Scholar 

Zhao N, Qin Y, Liu H, Cheng Z. Tumor-targeting peptides: ligands for molecular imaging and therapy. Anticancer Agents Med Chem. 2018;18(1):74–86.

Article  CAS  PubMed  Google Scholar 

Tang L, Li J, Pan T, Yin Y, Mei Y, Xiao Q, Wang R, Yan Z, Wang W. Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives. Theranostics. 2022;12(5):2290–321.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feynman R. There’s plenty of room at the bottom, Feynman and computation. Boca Raton: CRC Press; 2018. p. 63–76.

Google Scholar 

Guidance D. Guidance for industry considering whether an FDA-regulated product involves the application of nanotechnology. Biotechnol Law Rep. 2011;30(5):613–6.

Article  Google Scholar 

Rai M, Ingle A. Role of nanotechnology in agriculture with special reference to management of insect pests. Appl Microbiol Biotechnol. 2012;94(2):287–93.

Article  CAS  PubMed  Google Scholar 

Frietas R Jr. Nanomedicine: basic capabilities. Austin Landes Biosci. 1999;1:1.

Google Scholar 

Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12(7):3028–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nirmala MJ, Kizhuveetil U, Johnson A. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC Adv. 2023;13(13):8606–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barenholz, Y.C., Doxil®—The first FDA-approved nano-drug: From an idea to a product, in Handbook of harnessing biomaterials in nanomedicine. 2021, Jenny Stanford Publishing. p. 463–528.

Lee VJ, Divyesh M, Latha R. Abraxane® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest New Drugs. 2006;24(5):455–6.

Article  Google Scholar 

Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boehnke N, Straehla JP, Safford HC, Kocak M, Rees MG, Ronan M, Rosenberg D, Adelmann CH, Chivukula RR, Nabar N, et al. Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery. Science. 2022;377(6604):eabm5551.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16.

Article  CAS  PubMed  Google Scholar 

Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632–44.

Article  CAS  PubMed  Google Scholar 

Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–71.

Article  CAS  PubMed  Google Scholar 

Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maeda H. The 35th anniversary of the discovery of EPR Effect: a new wave of nanomedicines for tumor-targeted drug delivery-personal remarks and future prospects. J Pers Med. 2021;11(3):229.

Article  PubMed  PubMed Central  Google Scholar 

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–92.

CAS  PubMed  Google Scholar